Actonel (risedronate) is a bisphosphonate medication used to treat osteoporosis, which is taken orally. The use of oral bisphosphonate medications, such as Fosamax and Actonel, have been linked to an increased occurrence of osteonecrosis of the jaw, a painful and potentially disfiguring jaw bone condition. Recent studies have also indicated that oral bisphosphonates may cause osteonecrosis of other bones, such as the shoulder, hip and knee, as well as spontaneous femur fractures.
There have not been any indications that patients should not take oral bisphosphonates, such as Actonel and Fosamax, for treatment of osteporosis. However, many experts agree that it is important that the manufacturers warn patients about the increased risk of osteonecrosis of the jaw and other potential Actonel health problems associated with long term use.
Those taking bisphosphonates, such as Fosamax, Actonel, Aredia or Zometa, should notify their dentist or dental surgeon before any treatment. Elective dental procedures should be avoided, and for necessary procedures precautions should be taken to minimize the risk of osteonecrosis of the jaw.
ACTONEL BISPHOSPHONATE LAWSUITS
Saiontz and Kirk is currently investigating Fosamax lawsuit claims against the drug manufacturer for failing to warn patients and dentists of the known side effect associated with their osteoporosis medication. At this time we are reviewing the potential for claims involving the use of Actonel as well, but are not currently accepting new cases.
If you have taken Actonel, Fosamax, or another bisphosponate, and been diagnosed with osteonecrosis of the jaw, osteonecrosis of the hip, osteonecrosis of the shoulder or osteonecrosis of the knee, request a free consultation to review your legal rights. You and your family may be entitled to compensation for this painful condition which could have been prevented.
